The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

The advocacy group I AM ALS secured $313 million in federal funding for its campaign to accelerate research and expand access to treatment.

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) ...

I AM ALS announced a major milestone in its Push for Progress campaign: thanks to our community of advocates and partners, we've secured $313 million in funding for ALS research in the 2026 federal ...

The MarketWatch News Department was not involved in the creation of this content. The First Synaptic Regenerative Drug, SPG302, Led to Slowed Disease Progression in ALS Patients LOS ANGELES, Nov. 4, ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved RELYVRIO™ ...

Four investigational ALS treatments failed in phase II studies, but CNM-Au8 and pridopidine showed promising trends. The platform trial pooled placebo data across studies, allowing more ALS patients ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

The Food and Drug Administration on Friday approved Radicava — a new treatment for amyotrophic lateral sclerosis, or Lou Gehrig’s disease. Here are five things to know. 1. Radicava marks the first FDA ...

The National Academies of Sciences, Engineering, and Medicine are private, nonprofit institutions that provide expert advice on some of the most pressing challenges facing the nation and world. Our ...